The Effectiveness of ACB-IP 1.0 Convalescent Plasma in COVID-19 Infection
NCT ID: NCT04769245
Last Updated: 2021-02-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
40 participants
OBSERVATIONAL
2021-02-18
2021-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
COVID-19 With Convalescent Plasma
NCT04616976
Expanded Access to Convalescent Plasma to Treat and Prevent Pulmonary Complications Associated With COVID-19
NCT04358211
Efficacy of Convalescent Plasma Therapy in the Early Care of COVID-19 Patients.
NCT04372979
Convalescent Plasma Therapy on Critically-ill Novel Coronavirus (COVID-19) Patients
NCT04441424
Convalescent Plasma Transfusion in Severe COVID-19 Patients in Jamaica
NCT04644198
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Single donor convalescent plasma
Patients who had positive reverse-transcriptase-polymerase-chain-reaction (RT-PCR) for SARS-CoV2 and radiologically confirmed pneumonia treated with single donor plasma
No interventions assigned to this group
ACB- IP 1.0
Patients who had positive reverse-transcriptase-polymerase-chain-reaction (RT-PCR) for SARS-CoV2 and radiologically confirmed pneumonia treated with ACB- IP 1.0 pathogen-free concentrated cocktail convalescent plasma
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Between the ages of 18-60, serious comorbidities (cancer, COPD, cardiovascular illness, hypertension, DM)
* Clinically diagnose COVID-19 or radiological diagnosed COVID-19 pnemonia
Exclusion Criteria
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Acıbadem Labcell
OTHER
Acibadem University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Acıbadem Labcell Cellular Therapy Laboratories
Istanbul, , Turkey (Türkiye)
Acibadem Altunizade Hospital
Istanbul, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Cansu Hemsinlioglu, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Acibadem Healthcare Group
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.